UCL Technology Fund has approved investment of up to £1m in the development of a gene therapy for p47-CGD

The UCL Technology Fund (UCLTF), has approved an investment of up to £1m to support Professor Adrian Thrasher, Professor Bobby Gaspar, and Dr Giorgia Santilli’s development of a gene therapy for p47phox-deficient chronic granulomatous disease (p47-CGD) through to a clinical trial in which it could potentially cure patients completely of this devastating disease. p47-CGD is a […]

Read more

Professor John Greenwood speaks at the UCLTF lunchtime seminar in the Quad

Can you be a basic scientist and still translate your research? Being a scientist interested in fundamental mechanisms and being able to identify therapeutic and commercial opportunity are not mutually exclusive activities. It’s about learning to recognise commercial opportunity in your research, scientifically prove its potential and understand the pathway to development. This often takes […]

Read more

UCLTF fund drug development platform Canbex for the treatment of multiple sclerosis

Canbex was established to develop the VSN compound series, a drug development platform with potential applications in a wide range of therapeutic areas due to its mechanism of action. The lead molecule of the series, VSN16R, is in a Phase II trial for the treatment of spasticity in people with multiple sclerosis.  

Read more

Orchard Therapeutics Ltd. Announces a Manufacturing Alliance with PharmaCell B.V.

Orchard announces an alliance with PharmaCell B.V. (“PharmaCell”), a leading Contract Manufacturing Organization (CMO) for Cell and Gene Therapies and Regenerative Medicine. Under the terms of the alliance, PharmaCell will provide GMP-compliant manufacturing services to support clinical trials and commercialization of Orchard’s ex-vivo autologous gene therapy products. This agreement represents another important milestone for Orchard’s strategy […]

Read more

UCL Technology Fund invests £1m in to School of Pharmacy project to treat pancreatic cancer

  The UCL Technology Fund (UCLTF), which provides funding and support for UCL’s most transformative innovations, has approved an investment of up to £1m in Professor Stephen Neidle’s ‘G-Quadruplex’ Targeting project, which has the potential to treat pancreatic and other cancers. Pancreatic cancer is devastating and almost always refractory to treatment, resulting in rapid and […]

Read more

Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedica

Orchard Therapeutics has announced that it has entered into a strategic alliance with Oxford BioMedica plc., a world-leading company in gene and cell therapy. Under the terms of the collaboration and licence agreement, Oxford BioMedica has granted an exclusive intellectual property licence to Orchard for collaboration programmes, and will provide process development services and manufacture […]

Read more

Amit Nathwani of Freeline Therapeutics has received an Outstanding Achievement Award from the European Society for Gene and Cell Therapy

Freeline Therapeutics announced that The European Society for Gene and Cell Therapy (EGCST) has recognised the Company’s Founder and Chief Scientific Officer (CSO), Professor Amit Nathwani, with the Outstanding Achievement Award. ESGCT seeks to honour one eminent scientist each year who has made pioneering research success and a significant and lasting contribution to the advancement of the […]

Read more

Achilles Therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer

The UCL Technology Fund (UCLTF) announced its participation in the formation of Achilles Therapeutics Ltd, led by SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT). The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR). […]

Read more